3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Phase 1
1
Status
Completed
3
Unknown
2
Recruiting
2
Withdrawn
1
Available
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Sarcoma
2
Conditions
Multiple Myeloma
4
Sarcoma
2
Leukemia, Myeloid, Acute
2
Thymoma
1
Recurrence
1
Rectal Neoplasms
1
Neoplasm Metastasis
1
Lymphoma, T-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Drug-Related Side Effects and Adverse Reactions
1
Interventions
Doxorubicin
19
Radiotherapy
10
Ifosfamide
10
apatinib
9
anlotinib
8
Cyclophosphamide
8
camrelizumab
7
Vincristine
5
Dactinomycin
5
toripalimab
3
Trabectedin
3
Radiation Dose Hypofractionation
3
Ipilimumab
3
Gemcitabine
3
Etoposide
3
Docetaxel
3
selinexor
2
ribociclib
2
envafolimab
2
brostallicin
2
Topotecan
2
Thalidomide
2
Temozolomide
2
Sorafenib
2
Oncolytic Virotherapy
2
Nivolumab
2
Neoadjuvant Therapy
2
Melphalan
2
Magnetic Resonance Spectroscopy
2
Irinotecan
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Unknown
×
Sarcoma
×
selinexor
×
Clear all
NCT04595994
2024-01-23
SeliSarc
Grupo Espanol de Investigacion en Sarcomas
Phase 1
Unknown
14 enrolled
NCT04138381
2023-03-27
SeliGIST
Grupo Espanol de Investigacion en Sarcomas
Phase 1/2
Unknown
30 enrolled